Adagio was founded in 2011 by Dr. James Cox and Mr. Olav Bergheim. Their vision was to provide the electrophysiologist a set of tools to assist them in making the same continuous transmural endocardial lesions anywhere in the heart as the Cox-maze procedure has been doing epicardially. Additionally, the endocardial ablation had to be done on a beating heart with no restriction of blood flow.
The only practical energy source powerful enough to make such a continuous lesion is liquid nitrogen. While liquid nitrogen is well known to be the most powerful cryogen used in medical devices, it has the disadvantage that its volume expands approximately 200 times as it transitions from liquid state to gas state, and, therefore, it was never used as an endocardial cryogen.
The search for a technical solution brought us to Alex Babkin, PhD and his unique and powerful Near Critical Nitrogen (NCN) cryoablation technology that he had been developing since 2004. As is explained in our technology section, NCN provides the same powerful energy source as liquid nitrogen while solving the issue of volume expansion. Adagio acquired all technology and intellectual property from the development of Dr. Babkin, who is the Chief Technology Officer of Adagio. The company continues to focus on developing a cryo technology platform to make transmural ablation lines anywhere in the beating heart without restricting blood flow.
The flexibility of the Adagio technology gave the origin to ‘One Catheter. Unlimited Shapes.’
The technology is known as iCLAS, the Continuous Lesion Ablation System.